Clinical Trial Update: Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating furmonertinib as neoadjuvant therapy for resectable stage II–IIIb EGFR-sensitive mutant non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN